protein

TET2 recombinant protein

MBS515384

0.02 mg

345 USD

Recombinant Protein

TET2 recombinant protein

[TET2]

[Nbla00191; KIAA1546; MDS]

[Homo sapiens tet methylcytosine dioxygenase 2 (TET2), transcript variant 1, mRNA; Methylcytosine dioxygenase TET2; methylcytosine dioxygenase TET2; tet oncogene family member 2; probable methylcytosine dioxygenase TET2; tet methylcytosine dioxygenase 2]

[TET2]

[Nbla00191; KIAA1546; MDS]

[TET2; TET2; MDS; KIAA1546; KIAA1546]

TET2_HUMAN

9796

>70%

Recombinant protein stored in 50mM Tris-HCl, pH 7.5, 50mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM DTT, 0.1mM PMSF, 25% glycerol.

0.05 ug/ul

Store product at -70°C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles. Shipping: Ships with Dry Ice. Stability: 1 yr at -70°C from date of shipment.

Western Blot (WB)

SDS-PAGE

Methylcytosine Dioxygenase Proteins; Signaling Proteins - Methylcytosine Dioxygenase Proteins

Recombinant human TET2 (1197-end) was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag. Scientific Background: TET2 is a methylcytosine dioxygenase that catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine which is involved in myelopoiesis. Defects in TET2 gene have been associated with several myeloproliferative disorders. TET2 play an important role in embryonic stem cell maintenance and inner cell mass cell specification. TET proteins have potential roles in epigenetic regulation through modification of 5mC to 5hmC (1). TET2 enzymatic activity is involved in myeloid tumorigenesis and this could be valuable as a diagnostic and prognostic tool for targeted therapies and to assess responses to anticancer drugs (2).

1. Tahiliani, M. et.al: Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1.Science 324: 930-935, 2009. 2. Ko, M.et.al: Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468: 839-843, 2010.

325197189

NM_001127208

NM_001127208

Q6N021

The protein encoded by this gene is a methylcytosine dioxygenase that catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine. The encoded protein is involved in myelopoiesis, and defects in this gene have been associated with several myeloproliferative disorders. Two variants encoding different isoforms have been found for this gene. [provided by RefSeq, Mar 2011]

Function: Dioxygenase that catalyzes the conversion of the modified genomic base 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) and plays a key role in active DNA demethylation. Also mediates subsequent conversion of 5hmC into 5-formylcytosine (5fC), and conversion of 5fC to 5-carboxylcytosine (5caC). Conversion of 5mC into 5hmC, 5fC and 5caC probably constitutes the first step in cytosine demethylation. Methylation at the C5 position of cytosine bases is an epigenetic modification of the mammalian genome which plays an important role in transcriptional regulation. In addition to its role in DNA demethylation, also involved in the recruitment of the O-GlcNAc transferase OGT to CpG-rich transcription start sites of active genes, thereby promoting histone H2B GlcNAcylation by OGT. Ref.15 Ref.17 Ref.18 Ref.19 Ref.20. Catalytic activity: DNA 5-methylcytosine + 2-oxoglutarate + O2 = DNA 5-hydroxymethylcytosine + succinate + CO2. Cofactor: Binds 1 Fe2+ ion per subunit . By similarity. Subunit structure: Interacts with HCFC1 and OGT. Ref.19 Ref.20. Tissue specificity: Broadly expressed. Highly expressed in hematopoietic cells; highest expression observed in granulocytes. Expression is reduced in granulocytes from peripheral blood of patients affected by myelodysplastic syndromes. Ref.7 Ref.15. Post-translational modification: May be glycosylated. It is unclear whether interaction with OGT leads to GlcNAcylation. According to a report, it is not GlcNAcylated by OGT (Ref.19). In contrast, another group reports GlcNAcylation by OGT in mouse ortholog. Involvement in disease: TET2 is frequently mutated in myeloproliferative disorders (MPD). These constitute a heterogeneous group of disorders, also known as myeloproliferative diseases or myeloproliferative neoplasms (MPN), characterized by cellular proliferation of one or more hematologic cell lines in the peripheral blood, distinct from acute leukemia. Included diseases are: essential thrombocythemia, polycythemia vera, primary myelofibrosis (chronic idiopathic myelofibrosis). Bone marrow samples from patients display uniformly low levels of hmC in genomic DNA compared to bone marrow samples from healthy controls as well as hypomethylation relative to controls at the majority of differentially methylated CpG sites.Polycythemia vera (PV) [MIM:263300]: A myeloproliferative disorder characterized by abnormal proliferation of all hematopoietic bone marrow elements, erythroid hyperplasia, an absolute increase in total blood volume, but also by myeloid leukocytosis, thrombocytosis and splenomegaly.Note: The disease is caused by mutations affecting the gene represented in this entry.TET2 is frequently mutated in systemic mastocytosis; also known as systemic mast cell disease. A condition with features in common with myeloproliferative diseases. It is a clonal disorder of the mast cell and its precursor cells. The clinical symptoms and signs of systemic mastocytosis are due to accumulation of clonally derived mast cells in different tissues, including bone marrow, skin, the gastrointestinal tract, the liver, and the spleen.Myelodysplastic syndrome (MDS) [MIM:614286]: A heterogeneous group of closely related clonal hematopoietic disorders. All are characterized by a hypercellular or hypocellular bone marrow with impaired morphology and maturation, dysplasia of the myeloid, megakaryocytic and/or erythroid lineages, and peripheral blood cytopenias resulting from ineffective blood cell production. Included diseases are: refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS); chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative disease. MDS is considered a premalignant condition in a subgroup of patients that often progresses to acute myeloid leukemia (AML).Note: The disease is caused by mutations affecting the gene represented in this entry. Bone marrow samples from patients display uniformly low levels of hmC in genomic DNA compared to bone marrow samples from healthy controls as well as hypomethylation relative to controls at the majority of differentially methylated CpG sites. Ref.12 Ref.15 Ref.17. Sequence similarities: Belongs to the TET family. Caution: Subsequent steps in cytosine demethylation are subject to discussion. According to a first model cytosine demethylation occurs through deamination of 5hmC into 5-hydroxymethyluracil (5hmU) and subsequent replacement by unmethylated cytosine by the base excision repair system. According to another model, cytosine demethylation is rather mediated via conversion of 5hmC into 5fC and 5caC, followed by excision by TDG (Ref.18). Sequence caution: The sequence BAA90898.1 differs from that shown. Reason: Erroneous termination at position 325. Translated as Gln.The sequence BAA90898.1 differs from that shown. Reason: Frameshift at position 323. The sequence BAA90898.1 differs from that shown. Reason: Contaminating sequence. Potential poly-A sequence.The sequence BAB55391.1 differs from that shown. Reason: Erroneous initiation. Translation N-terminally extended.

0.02 mg

345 USD

0.05 mg

540